No HoFH definition could give Aegerion market lead with Juxtapid
This article was originally published in Scrip
Executive Summary
There was little question the US FDA would approve Aegerion Pharmaceuticals' Juxtapid (lomitapide), a microsomal triglyceride transfer protein inhibitor intended to treat patients with homozygous familial hyperchodlesterolemia (HoFH) – with that OK coming about a week ahead of its 29 December Prescription Drug User Fee Act action date.
You may also be interested in...
Ionis Sells Kynamro To Kastle After Regaining Rights From Genzyme
Three and a half months after Ionis Pharmaceuticals Inc. surprised investors with the news that Sanofi's Genzyme business unit would no longer market Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH), the Carlsbad, California-based biotechnology company revealed that it sold global rights to the cholesterol-lowering drug to Kastle Therapeutics LLC for up to $95m.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.